RU2008152435A - Композиции и способы регулирования развития сосудов - Google Patents
Композиции и способы регулирования развития сосудов Download PDFInfo
- Publication number
- RU2008152435A RU2008152435A RU2008152435/15A RU2008152435A RU2008152435A RU 2008152435 A RU2008152435 A RU 2008152435A RU 2008152435/15 A RU2008152435/15 A RU 2008152435/15A RU 2008152435 A RU2008152435 A RU 2008152435A RU 2008152435 A RU2008152435 A RU 2008152435A
- Authority
- RU
- Russia
- Prior art keywords
- dll4
- effective amount
- cancer
- antibody
- angiogenesis
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 33
- 239000000203 mixture Substances 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract 20
- 102100033553 Delta-like protein 4 Human genes 0.000 claims abstract 19
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims abstract 19
- 239000005557 antagonist Substances 0.000 claims abstract 17
- 201000010099 disease Diseases 0.000 claims abstract 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 12
- 230000033115 angiogenesis Effects 0.000 claims abstract 11
- 210000002889 endothelial cell Anatomy 0.000 claims abstract 11
- 230000001575 pathological effect Effects 0.000 claims abstract 11
- 230000000694 effects Effects 0.000 claims abstract 10
- 201000011510 cancer Diseases 0.000 claims abstract 9
- 210000004027 cell Anatomy 0.000 claims abstract 9
- 230000002062 proliferating effect Effects 0.000 claims abstract 9
- 230000035755 proliferation Effects 0.000 claims abstract 6
- 230000004069 differentiation Effects 0.000 claims abstract 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract 5
- 210000001367 artery Anatomy 0.000 claims abstract 4
- 230000036770 blood supply Effects 0.000 claims abstract 4
- 230000002792 vascular Effects 0.000 claims abstract 4
- 230000003313 weakening effect Effects 0.000 claims abstract 3
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract 2
- 206010025323 Lymphomas Diseases 0.000 claims abstract 2
- 239000000556 agonist Substances 0.000 claims abstract 2
- 201000002313 intestinal cancer Diseases 0.000 claims abstract 2
- 201000005202 lung cancer Diseases 0.000 claims abstract 2
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 2
- 201000001441 melanoma Diseases 0.000 claims abstract 2
- 230000004936 stimulating effect Effects 0.000 claims abstract 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
Abstract
1. Способ лечения опухоли, рака или клеточно-пролиферативного заболевания, включающий введение эффективного количества антагониста DLL4 в организм объекта, нуждающегося в подобном воздействии, посредством чего лечится опухоль, рак или клеточно-пролиферативное заболевание. ! 2. Способ по п.1, где опухоль, рак или клеточно-пролиферативное заболевание представляет собой рак кишечника, рак легкого, меланому или лимфому. ! 3. Способ лечения патологического состояния, связанного с ангиогенезом, включающий введение эффективного количества антагониста DLL4 в организм объекта, нуждающегося в подобном воздействии, посредством чего лечится патологическое состояние, связанное с ангиогенезом, где антагонист DLL4 способен стимулировать пролиферацию эндотелиальных клеток, ингибировать дифференцировку эндотелиальных клеток, ингибировать развитие артерий или ингибировать сосудистое кровоснабжение. ! 4. Способ по п.3, где патологическое состояние, связанное с ангиогенезом, представляет собой опухоль, рак и/или клеточно-пролиферативное заболевание. ! 5. Способ по п.3, где патологическое состояние, связанное с ангиогенезом, представляет собой глазное неоваскулярное заболевание. ! 6. Способ стимуляции пролиферации эндотелиальных клеток объекта, нуждающегося в подобном воздействии, включающий введение эффективного количества агониста DLL4 в организм объекта, посредством чего стимулируется пролиферация эндотелиальных клеток. ! 7. Способ ослабления или ингибирования дифференцировки эндотелиальных клеток объекта, нуждающегося в подобном воздействии, включающий введение эффективного количества антагониста DLL4 в организм объекта
Claims (25)
1. Способ лечения опухоли, рака или клеточно-пролиферативного заболевания, включающий введение эффективного количества антагониста DLL4 в организм объекта, нуждающегося в подобном воздействии, посредством чего лечится опухоль, рак или клеточно-пролиферативное заболевание.
2. Способ по п.1, где опухоль, рак или клеточно-пролиферативное заболевание представляет собой рак кишечника, рак легкого, меланому или лимфому.
3. Способ лечения патологического состояния, связанного с ангиогенезом, включающий введение эффективного количества антагониста DLL4 в организм объекта, нуждающегося в подобном воздействии, посредством чего лечится патологическое состояние, связанное с ангиогенезом, где антагонист DLL4 способен стимулировать пролиферацию эндотелиальных клеток, ингибировать дифференцировку эндотелиальных клеток, ингибировать развитие артерий или ингибировать сосудистое кровоснабжение.
4. Способ по п.3, где патологическое состояние, связанное с ангиогенезом, представляет собой опухоль, рак и/или клеточно-пролиферативное заболевание.
5. Способ по п.3, где патологическое состояние, связанное с ангиогенезом, представляет собой глазное неоваскулярное заболевание.
6. Способ стимуляции пролиферации эндотелиальных клеток объекта, нуждающегося в подобном воздействии, включающий введение эффективного количества агониста DLL4 в организм объекта, посредством чего стимулируется пролиферация эндотелиальных клеток.
7. Способ ослабления или ингибирования дифференцировки эндотелиальных клеток объекта, нуждающегося в подобном воздействии, включающий введение эффективного количества антагониста DLL4 в организм объекта, посредством чего ингибируется дифференцировка эндотелиальных клеток.
8. Способ ослабления или ингибирования развития артерий у объекта, нуждающегося в подобном воздействии, включающий введение эффективного количества антагониста DLL4 в организм объекта, посредством чего ингибируется развитие артерий.
9. Способ ослабления или ингибирования сосудистого кровоснабжения опухоли у объекта, нуждающегося в подобном воздействии, включающий введение эффективного количества антагониста DLL4 в организм объекта, посредством чего ингибируется сосудистое кровоснабжение опухоли.
10. Способ по любому из пп.1-5, 7-9, дополнительно включающий введение в организм объекта эффективного количества анти-ангиогенного агента.
11. Способ по п.10, где анти-ангиогенный агент вводится перед или после антагониста DLL4.
12. Способ по п.10, где анти-ангиогенный агент вводится одновременно с антагонистом DLL4.
13. Способ по любому из пп.11-12, где анти-ангиогенный агент представляет собой антагонист фактора роста сосудистого эндотелия (VEGF).
14. Способ по п.13, где антагонист VEGF представляет собой антитело к VEGF.
15. Способ по п.14, где антитело к VEGF представляет собой бевацизумаб.
16. Способ по любому из пп.1-5, 7-9, 11, 12, 14 и 15, дополнительно включающий введение эффективного количества химиотерапевтического агента.
17. Способ повышения эффективности анти-ангиогенного агента у объекта, страдающего от патологического состояния, связанного с ангиогенезом, включающий введение в организм объекта эффективного количества антагониста DLL4 в комбинации с анти-ангиогенным агентом, таким образом повышая ингибиторную активность указанного анти-ангиогенного агента.
18. Способ по п.17, где патологическое состояние, связанное с ангиогенезом, представляет собой опухоль, рак и/или клеточно-пролиферативное заболевание.
19. Способ по п.17, где патологическое состояние, связанное с ангиогенезом, представляет собой внутриглазное неоваскулярное заболевание.
20. Способ по любому из пп.1-5, 7-9, 11, 12, 14, 15 и 17-19, где антагонист DLL4 представляет собой антитело к DLL4.
21. Способ по любому из пп.1-5, 7-9, 11, 12, 14, 15 и 17-19, где антагонист DLL4 представляет собой иммуноадгезин DLL4.
22. Способ по п.20, где антитело к DLL4 представляет собой моноклональное антитело.
23. Способ по п.20, где антитело к DLL4 представляет собой человеческое антитело, гуманизированное антитело или химерное антитело.
24. Способ по п.20, где антитело к DLL4 представляет собой фрагмент антитела.
25. Способ по п.24, где фрагмент антитела представляет собой Fab, Fab', Fab'-SH, F(ab')2 или scFv.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81135706P | 2006-06-06 | 2006-06-06 | |
| US60/811,357 | 2006-06-06 | ||
| US86676706P | 2006-11-21 | 2006-11-21 | |
| US60/866,767 | 2006-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008152435A true RU2008152435A (ru) | 2010-07-20 |
Family
ID=38626647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008152435/15A RU2008152435A (ru) | 2006-06-06 | 2007-06-06 | Композиции и способы регулирования развития сосудов |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20080014196A1 (ru) |
| EP (1) | EP2029159A2 (ru) |
| JP (1) | JP2009539870A (ru) |
| KR (1) | KR20090016762A (ru) |
| AR (1) | AR061245A1 (ru) |
| AU (1) | AU2007256617A1 (ru) |
| BR (1) | BRPI0710411A2 (ru) |
| CA (1) | CA2654304A1 (ru) |
| CL (1) | CL2007001624A1 (ru) |
| CR (1) | CR10529A (ru) |
| EC (1) | ECSP099032A (ru) |
| IL (1) | IL194788A0 (ru) |
| MA (1) | MA30536B1 (ru) |
| MX (1) | MX2008015532A (ru) |
| NO (1) | NO20090046L (ru) |
| RU (1) | RU2008152435A (ru) |
| SG (1) | SG172687A1 (ru) |
| TW (1) | TW200817435A (ru) |
| WO (1) | WO2007143689A2 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2581962C2 (ru) * | 2008-09-19 | 2016-04-20 | Медиммун Ллк | Нацеленные средства связывания, направленные на dll4, и их применение |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| US7906116B2 (en) * | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| ES2400666T5 (es) * | 2005-12-16 | 2016-03-10 | Regeneron Pharmaceuticals, Inc. | Uso terapéutico de un antagonista de DII4 y un inhibidor de VEGF para inhibir el crecimiento tumoral |
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| PL2054082T3 (pl) | 2006-08-07 | 2013-05-31 | Regeneron Pharma | Zastosowanie antagonistów DII4 w uszkodzeniach niedokrwiennych i niewydolności naczyniowej |
| KR101477824B1 (ko) * | 2006-09-29 | 2015-01-02 | 온코메드 파마슈티칼스, 인크. | 암의 진단 및 치료를 위한 조성물 및 방법 |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| WO2008092002A2 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
| JP2010517944A (ja) * | 2007-01-26 | 2010-05-27 | バイオインヴェント インターナショナル アーベー | Ｄｌｌ４シグナリング阻害薬およびその使用 |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| AR070032A1 (es) | 2007-11-09 | 2010-03-10 | Genentech Inc | Composiciones y metodos de uso de antagonistas quinasa-1 similar al receptor de la activina (alk-1) |
| JP2011516520A (ja) * | 2008-04-07 | 2011-05-26 | アブリンクス エン．ヴェー． | Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用 |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| NZ588554A (en) * | 2008-04-29 | 2013-03-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2009137807A2 (en) | 2008-05-08 | 2009-11-12 | Asuragen, Inc. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
| CA2726087A1 (en) * | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| CN102112494A (zh) * | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
| CA2729949A1 (en) * | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| PT2307051E (pt) | 2008-07-08 | 2015-05-21 | Oncomed Pharm Inc | Antagonistas e agentes de ligação a notch e métodos de utilização dos mesmos |
| JP2012508017A (ja) * | 2008-11-07 | 2012-04-05 | ファブラス エルエルシー | 抗ｄｌｌ４抗体及びその使用 |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| MX336152B (es) | 2009-08-29 | 2016-01-08 | Abbvie Inc | Proteinas terapeutico de union a dll4. |
| UY32870A (es) * | 2009-09-01 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| US20110195494A1 (en) | 2009-10-02 | 2011-08-11 | Boehringer Ingelheim International Gmbh | Dll4-binging molecules |
| CA2775959A1 (en) * | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| WO2011047383A1 (en) * | 2009-10-16 | 2011-04-21 | Oncomed Pharmaceuticals, Inc. | Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2493497A4 (en) * | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME |
| EP2506875A4 (en) * | 2009-12-01 | 2013-11-27 | Oncomed Pharm Inc | METHOD FOR THE TREATMENT OF TUMORS WITH K-RAS MUTATIONS |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| CN102958534B (zh) | 2010-01-13 | 2014-11-05 | 昂考梅德药品有限公司 | Notch1结合剂及其使用方法 |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| RU2016146198A (ru) | 2010-03-02 | 2018-12-19 | Эббви Инк. | Терапевтические dll4-связывающие белки |
| AU2011285852B2 (en) | 2010-08-03 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| PH12013500337A1 (en) | 2010-08-26 | 2017-08-23 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
| US20120225081A1 (en) | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| KR101330184B1 (ko) * | 2010-10-15 | 2013-11-15 | 성균관대학교산학협력단 | 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US20130078247A1 (en) * | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
| LT2758073T (lt) | 2011-09-23 | 2019-01-10 | Oncomed Pharmaceuticals, Inc. | Vegf/dll4 surišantys agentai ir jų panaudojimas |
| CN104159920A (zh) | 2011-12-30 | 2014-11-19 | 艾伯维公司 | 针对il-13和/或il-17的双重可变结构域免疫球蛋白 |
| CN104220603B (zh) | 2012-02-10 | 2017-06-06 | 马里兰大学，巴尔的摩 | 抗体及其Fc片段的化学酶法糖基化工程 |
| SI2831111T1 (sl) | 2012-03-30 | 2019-06-28 | Boehringer Ingelheim International Gmbh | Ang2-vezavne molekule |
| BR112014027983B1 (pt) | 2012-05-08 | 2022-05-24 | Aeromics, Inc | Uso de inibidores de aquaporina seletivos |
| EA201500370A1 (ru) | 2012-09-28 | 2015-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ |
| CA2883880A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents |
| US20140227252A1 (en) | 2012-10-31 | 2014-08-14 | Oncomed Pharmaceuticals , Inc. | Methods and Monitoring of Treatment with a DLL4 Antagonist |
| KR20180008921A (ko) | 2012-11-01 | 2018-01-24 | 애브비 인코포레이티드 | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 |
| AR093445A1 (es) | 2012-11-14 | 2015-06-10 | Regeneron Pharma | Metodos para tratar el cancer de ovario con antagonistas de dll4 |
| EP2970459A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Dual specific binding proteins directed against il-1beta and il-17 |
| CA2929821A1 (en) | 2013-11-06 | 2015-05-14 | Aeromics, Inc. | 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate formulations and kits |
| CA2966042A1 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| WO2017053705A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
| US11026996B2 (en) * | 2016-05-25 | 2021-06-08 | The Trustees Of Columbia University In The City Of New York | Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling |
| US20220185875A1 (en) | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) * | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2089661C (en) * | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US20030206899A1 (en) * | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| WO1992022653A1 (en) * | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| US5545007A (en) * | 1994-11-25 | 1996-08-13 | United Technologies Corp. | Engine blade clearance control system with piezoelectric actuator |
| US20060122373A1 (en) * | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
| US6121045A (en) * | 1997-04-04 | 2000-09-19 | Millennium Biotherapeutics, Inc. | Human Delta3 nucleic acid molecules |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| EP1787999B1 (en) * | 1997-04-07 | 2010-08-04 | Genentech, Inc. | Anti-VEGF antibodies |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| CA2288218C (en) * | 1997-05-14 | 2013-03-12 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel differentiation-inhibitor |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) * | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2278003B2 (en) * | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| PT1292335E (pt) * | 2000-06-23 | 2007-08-13 | Bayer Schering Pharma Ag | Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii) |
| US7064191B2 (en) * | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| DK1443961T3 (da) * | 2001-10-25 | 2009-08-24 | Genentech Inc | Glycoprotein-sammensætninger |
| US20040093621A1 (en) * | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20040110704A1 (en) * | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
| JPWO2003085118A1 (ja) * | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| WO2003085119A1 (en) * | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
| AU2003236019A1 (en) * | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
| CA2481920A1 (en) * | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| EP1500698B1 (en) * | 2002-04-09 | 2011-03-30 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| RS20181002A1 (sr) * | 2003-05-30 | 2018-12-31 | Genentech Inc | Tretman sa anti-vegf antitelima |
| EP1705251A4 (en) * | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
| EA025962B1 (ru) * | 2003-11-05 | 2017-02-28 | Роше Гликарт Аг | АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ |
| US20060134121A1 (en) * | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| US20070213266A1 (en) * | 2005-09-01 | 2007-09-13 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of Delta-like 4 |
| ES2400666T5 (es) * | 2005-12-16 | 2016-03-10 | Regeneron Pharmaceuticals, Inc. | Uso terapéutico de un antagonista de DII4 y un inhibidor de VEGF para inhibir el crecimiento tumoral |
-
2007
- 2007-06-06 RU RU2008152435/15A patent/RU2008152435A/ru not_active Application Discontinuation
- 2007-06-06 EP EP07798174A patent/EP2029159A2/en not_active Withdrawn
- 2007-06-06 WO PCT/US2007/070516 patent/WO2007143689A2/en not_active Ceased
- 2007-06-06 TW TW096120337A patent/TW200817435A/zh unknown
- 2007-06-06 US US11/759,093 patent/US20080014196A1/en not_active Abandoned
- 2007-06-06 BR BRPI0710411-1A patent/BRPI0710411A2/pt not_active IP Right Cessation
- 2007-06-06 CA CA002654304A patent/CA2654304A1/en not_active Abandoned
- 2007-06-06 CL CL2007001624A patent/CL2007001624A1/es unknown
- 2007-06-06 KR KR1020097000079A patent/KR20090016762A/ko not_active Withdrawn
- 2007-06-06 JP JP2009514512A patent/JP2009539870A/ja active Pending
- 2007-06-06 AR ARP070102434A patent/AR061245A1/es not_active Application Discontinuation
- 2007-06-06 SG SG2011041456A patent/SG172687A1/en unknown
- 2007-06-06 MX MX2008015532A patent/MX2008015532A/es unknown
- 2007-06-06 AU AU2007256617A patent/AU2007256617A1/en not_active Abandoned
-
2008
- 2008-10-22 IL IL194788A patent/IL194788A0/en unknown
- 2008-12-18 CR CR10529A patent/CR10529A/es not_active Application Discontinuation
- 2008-12-26 MA MA31521A patent/MA30536B1/fr unknown
-
2009
- 2009-01-05 NO NO20090046A patent/NO20090046L/no not_active Application Discontinuation
- 2009-01-06 EC EC2009009032A patent/ECSP099032A/es unknown
- 2009-07-02 US US12/497,405 patent/US20100129356A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2581962C2 (ru) * | 2008-09-19 | 2016-04-20 | Медиммун Ллк | Нацеленные средства связывания, направленные на dll4, и их применение |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200817435A (en) | 2008-04-16 |
| SG172687A1 (en) | 2011-07-28 |
| ECSP099032A (es) | 2009-02-27 |
| BRPI0710411A2 (pt) | 2012-04-10 |
| NO20090046L (no) | 2009-03-06 |
| WO2007143689A8 (en) | 2008-05-08 |
| CL2007001624A1 (es) | 2008-01-18 |
| IL194788A0 (en) | 2011-08-01 |
| CR10529A (es) | 2009-03-02 |
| WO2007143689A2 (en) | 2007-12-13 |
| EP2029159A2 (en) | 2009-03-04 |
| US20080014196A1 (en) | 2008-01-17 |
| WO2007143689A3 (en) | 2008-02-14 |
| US20100129356A1 (en) | 2010-05-27 |
| AU2007256617A1 (en) | 2007-12-13 |
| JP2009539870A (ja) | 2009-11-19 |
| MX2008015532A (es) | 2008-12-18 |
| CA2654304A1 (en) | 2007-12-13 |
| MA30536B1 (fr) | 2009-06-01 |
| KR20090016762A (ko) | 2009-02-17 |
| AR061245A1 (es) | 2008-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008152435A (ru) | Композиции и способы регулирования развития сосудов | |
| Schlaeppi et al. | Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors | |
| Fischer et al. | Anti-PlGF inhibits growth of VEGF (R)-inhibitor-resistant tumors without affecting healthy vessels | |
| JP2009539870A5 (ru) | ||
| Wu et al. | The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma | |
| Jain | Tumor angiogenesis and accessibility: role of vascular endothelial growth factor | |
| Spaide | Rationale for combination therapies for choroidal neovascularization | |
| Moore et al. | Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells | |
| Song et al. | Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery | |
| Peng et al. | Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models | |
| US20200147084A1 (en) | Tec family kinase inhibitor adjuvant therapy | |
| Ferrara et al. | Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy | |
| Grzegorzewska et al. | Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways | |
| Yan et al. | 3D mathematical modeling of glioblastoma suggests that transdifferentiated vascular endothelial cells mediate resistance to current standard-of-care therapy | |
| Zhang et al. | Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy | |
| Weiss et al. | Low‐dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization | |
| Bellone et al. | Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease | |
| Semeraro et al. | Pharmacokinetic and pharmacodynamic properties of anti-VEGF drugs after intravitreal injection | |
| Bhuvaneswari et al. | Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins | |
| Kohandel et al. | Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies | |
| Stachura et al. | The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development | |
| JP5671487B2 (ja) | 放射線治療の有効性を増強するためのｍｅｔ阻害剤 | |
| Pourgholami et al. | Inhibitors of vascular endothelial growth factor in cancer | |
| EP2817028A1 (en) | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer | |
| Bhuvaneswari et al. | Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20120725 |